Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand‐foot syndrome

Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand‐foot syndrome (HFS) or palmar‐plantar erythrodysesthesia. Genetic variation in ST6GAL1 is a risk factor for type‐2 diabetes (T2D), a disease also associated with HFS. We analysed genome‐wide association data for 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Watts, Katie, Wills, Christopher, Madi, Ayman, Palles, Claire, Maughan, Timothy S., Kaplan, Richard, Al‐Tassan, Nada A., Kerr, Rachel, Kerr, David J., Houlston, Richard S., Escott‐Price, Valentina, Cheadle, Jeremy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545609/
https://www.ncbi.nlm.nih.gov/pubmed/35467766
http://dx.doi.org/10.1002/ijc.34046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545609/
https://www.ncbi.nlm.nih.gov/pubmed/35467766
http://dx.doi.org/10.1002/ijc.34046

Ejemplares similares